mRNA Provides Significant Long-Term Investment Opportunities

Investment Insights

The success of the mRNA-based vaccine for the COVID-19 virus established that mRNA technology is highly effective in improving the body’s immune response. Messenger ribonucleic acid (mRNA) vaccines are faster and easier to mass-produce than traditional vaccines. This feature enabled biopharma companies to invest in and produce mRNA-based COVID-19 vaccines on a large scale, which was necessary to combat the pandemic. But how does one keep fundamentals over frenzy and identify the best-placed beneficiaries? And will the capital raising activity continue to remain that strong? 

Key Takeaways:
•    The mRNA vaccine technology promises a huge growth potential to biopharma companies.
•    After the recent success of mRNA vaccines to fight against the COVID-19 virus, companies are participating in M&A and fundraising activities.
•    While mRNA is still in its infancy stage, the fight against COVID-19 has served as a significant testing ground for the technology.
•    Companies are now exploring the possibility as well as the benefits of mRNA vaccines to treat other diseases.

To know more...


Related Topics

White Paper Digital Innovations Transform Investment Research

White Papers

Digital Innovations Transform Investment Research

In investment research, technology has become a key enabler providing faster access to actionable insights. Digital innovations in investment research, such...

SGA Whitepaper - FIFA World Cup Qatar 2022

White Papers

FIFA World Cup Qatar 2022 - Sports Spectacle in the Middle...

Qatar is all set to welcome the FIFA World Cup in 2022. In December 2010, the former FIFA president announced that 22 executive committee members had voted...

We bring comprehensive data driven insights to everyone, everywhere